Status
Conditions
About
The "Pharmacogenomics of Stimulant Treatment Response" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-17 with Attention deficit/hyperactivity disorder (ADHD).
Full description
Background: ADHD is a common neurodevelopmental disorder affecting children and adolescents, with psychostimulants, specifically slow-release methylphenidate (e.g., Biphentin®, Concerta®), being a first-line treatment option. However, the response to medications varies significantly among individuals, with some experiencing limited benefits or intolerable side effects. Unlike other areas of psychiatry, ADHD pharmacotherapy lacks genetic markers to guide treatment decisions, resulting in delayed symptom relief and diminished quality of life for patients.
Objectives:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients will be eligible for participation if all the following are true.
Exclusion criteria
Patients will be excluded from participation if any of the following are true.
Loading...
Central trial contact
Madison Heintz, MSW
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal